Misonix Features New BoneScalpel® MIS at SpineWeek 2016 In Singapore

FARMINGDALE, N.Y., May 16, 2016 /PRNewswire/ — Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, today announced that it will be exhibiting at the 2016 SpineWeek conference in Singapore, to take place from May 16 to May 20, 2016.

Surgeon attendees at this important global conference from all over the world will have the opportunity to trial the BoneScalpel, and the newly launched minimally invasive spinal solution BoneScalpel MIS, in a hands-on session at the exhibition.

Scott Ludecker, Senior Vice President of Global Sales & Marketing, commented, “Advancements like BoneScalpel MIS are enabling minimally invasive spine procedures that have less post-operative pain, are safer, and potentially return patients to their normal activities sooner than otherwise possible with open procedures. Additionally, the BoneScalpel MIS has been referred to as a ‘game changer’ by a number of opinion leading surgeons and continues to gain acceptance around the world. Participation in SpineWeek this year will serve as a great forum for Misonix to continue its growth into the Asian markets.”

“SpineWeek 2016 in Singapore represents a great opportunity for the team at Misonix to formally introduce our newest surgical solutions to our expanding base of surgeon customers already using BoneScalpel in this part of the world. We will also have the opportunity to demonstrate the unique clinical benefits of BoneScalpel to new customers in hands-on sessions. Misonix recently reported worldwide revenues from BoneScalpel increased 41% in our third quarter. We look forward to continuing to build on this exciting growth with the addition of new surgeon customers as a result of their hands-on experience at SpineWeek.” addedMichael A. McManus Jr., President and Chief Executive Officer of Misonix.

About Misonix
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.

Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company’s Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact: Investor Contact:
Richard Zaremba Joe Diaz & Lytham Partners
631-694-9555 602-889-9700
invest@misonix.com info@misonix.com

Logo – http://photos.prnewswire.com/prnh/20160201/328020LOGO


SOURCE Misonix, Inc.

Related Links


Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button